Published Year: 2021
Global Flow Cytometry in Oncology Market: Focus on Product Type, Technology, Type of Cancer, Applica
The global market for flow cytometry in oncology is predicted to grow at a CAGR of 12.02% over...
Market Research Report
A quick peek into the report
Table of Contents
1.1 Global Market Outlook
1.1.1 Product Definition
1.1.2 Inclusion and Exclusion Criteria
1.2 Market Overview
1.2.1 Application of Flow Cytometry in Oncology
1.2.1.1 Solid Tumor
1.2.1.2 Hematological Malignancies
1.2.2 Addressable Market Size and Growth Potential ($Million), 2021-2032
1.3 Industry Participants Landscape
2.1 Regulatory Framework
2.1.1 Regulatory Framework in the U.S.
2.1.1.1 Recommendations for Diagnostic Approval
2.1.2 Regulatory Framework in Europe
2.1.2.1 Recommendations for Diagnostic Approval
2.1.3 Regulatory Framework in Asia-Pacific
2.1.3.1 China
2.1.3.1.1 Recommendations for Diagnostic Approval
2.1.3.2 Japan
2.1.3.2.1 Recommendations for Diagnostic Approval
2.2 Reimbursement Scenario
2.2.1 North America
2.2.2 Europe
2.2.3 Asia-Pacific
2.3 Product Mapping Analysis
2.3.1 Global Flow Cytometry in Oncology and Immunology Market, Product Mapping Analysis (by Offering)
2.3.2 Global Flow Cytometry in Oncology and Immunology Market, Product Mapping Analysis, (by Product)
2.3.3 Price Sensitivity Analysis
2.4 Impact of COVID-19 on Global Flow Cytometry in Oncology and Immunology Market
2.4.1 Impact of COVID-19 on Flow Cytometry Research
2.4.2 Pre-COVID-19 Phase
2.4.3 During-COVID-19 Phase
2.4.4 Post-COVID-19 Phase
2.5 Business Dynamics
2.5.1 Impact Analysis
2.5.2 Business Drivers
2.5.2.1 Increasing Burden of Cancer is One of the Major Propelling Factors for the Innovation of Novel Technologies in Flow Cytometry
2.5.2.2 Expansion of Applications in Flow Cytometry for Research Activities Propels its Demand in the Market
2.5.2.3 Innovation in Flow Cytometry Leading to Use of Next-Generation Flow Cytometers
2.5.2.4 Increasing Use of Flow Cytometry in Identification and Diagnosis of Immune-Deficiency Diseases
2.5.3 Business Restraints
2.5.3.1 High Cost of the Products of the Flow Cytometry Equipment Restraining the Adoption of the Devices in Emerging Economies
2.5.3.2 False Negative and Positive Antibody Responses Can Hinder the Adoption of Flow Cytometry
2.5.4 Business Opportunities
2.5.4.1 Flow Cytometry as a Pivoting Technology in Solid Tumors in the Next 5-10 years
2.5.4.2 Leveraging Public-Private Initiatives to Advance R&D in the Field of Immunology and Oncology Research
3.1 Opportunity Assessment
3.2 Cell-Based Flow Cytometry
3.3 Bead-Based Flow Cytometry
4.1 Opportunity Assessment
4.2 Products
4.2.1 Instruments
4.2.2 Reagents and Consumables
4.2.3 Software
4.3 Services
5.1 Opportunity Assessment
5.2 Translational Research
5.3 Clinical Research
5.3.1 Screening and Diagnostics
5.3.2 Monitoring and Treatment
6.1 Opportunity Assessment
6.2 Immunology
6.3 Oncology
6.3.1 Hematological Malignancies
6.3.1.1 Hematological Malignancies (by Type)
6.3.1.1.1 Lymphoma
6.3.1.1.2 Leukemia
6.3.1.1.3 Myeloma
6.3.1.1.4 Other Hematological Malignancies
6.3.1.2 Hematological Malignancies (by Technology)
6.3.2 Solid Tumor
6.3.2.1 Solid Tumor (by Type)
6.3.2.1.1 Breast Cancer
6.3.2.1.2 Prostate Cancer
6.3.2.1.3 Colorectal Cancer
6.3.2.1.4 Lung Cancer
6.3.2.1.5 Liver Cancer
6.3.2.1.6 Ovarian Cancer
6.3.2.1.7 Other Solid Tumors
6.3.2.2 Solid Tumor (by Technology)
7.1 Opportunity Assessment
7.2 Hospitals, Diagnostic Laboratories, and Reference Laboratories
7.3 Pharmaceutical and Biotechnology Companies
7.4 Academic Research Institutes
7.5 Contract Research Organizations
7.6 Others
8.1 North America Flow Cytometry in Oncology and Immunology Market
8.1.1 Key Findings and Opportunity Assessment
8.1.2 Market Dynamics
8.1.2.1 Impact Analysis
8.1.3 Market Sizing and Forecast
8.1.4 North America Flow Cytometry in Oncology and Immunology Market (by Country)
8.1.4.1 U.S.
8.1.4.1.1 Market Dynamics
8.1.4.1.2 Cancer Incidence (by Type of Cancer)
8.1.4.1.3 Market Size and Forecast
8.1.4.1.3.1 U.S. Flow Cytometry in Oncology and Immunology Market (by Application)
8.1.4.1.3.2 U.S. Flow Cytometry in Oncology and Immunology Market (by Type of Cancer)
8.1.4.2 Canada
8.1.4.2.1 Market Dynamics
8.1.4.2.2 Cancer Incidence (by Type of Cancer)
8.1.4.2.3 Market Size and Forecast
8.1.4.2.3.1 Canada Flow Cytometry in Oncology and Immunology Market (by Application)
8.1.4.2.3.2 Canada Flow Cytometry in Oncology and Immunology Market (by Type of Cancer)
8.2 Europe Flow Cytometry in Oncology and Immunology Market
8.2.1 Key Findings and Opportunity Assessment
8.2.2 Market Dynamics
8.2.2.1 Impact Analysis
8.2.3 Market Sizing and Forecast
8.2.4 Europe Flow Cytometry in Oncology and Immunology Market (by Country)
8.2.4.1 Germany
8.2.4.1.1 Market Dynamics
8.2.4.1.2 Cancer Incidence (by Type of Cancer)
8.2.4.1.3 Market Size and Forecast
8.2.4.1.3.1 Germany Flow Cytometry in Oncology and Immunology Market (by Application)
8.2.4.1.3.2 Germany Flow Cytometry in Oncology and Immunology Market (by Type of Cancer)
8.2.4.2 France
8.2.4.2.1 Market Dynamics
8.2.4.2.2 Cancer Incidence (by Type of Cancer)
8.2.4.2.3 Market Size and Forecast
8.2.4.2.3.1 France Flow Cytometry in Oncology and Immunology Market (by Application)
8.2.4.2.3.2 France Flow Cytometry in Oncology and Immunology Market (by Type of Cancer)
8.2.4.3 U.K.
8.2.4.3.1 Market Dynamics
8.2.4.3.2 Cancer Incidence (by Type of Cancer)
8.2.4.3.3 Market Size and Forecast
8.2.4.3.3.1 U.K. Flow Cytometry in Oncology and Immunology Market (by Application)
8.2.4.3.3.2 U.K. Flow Cytometry in Oncology and Immunology Market (by Type of Cancer)
8.2.4.4 Italy
8.2.4.4.1 Market Dynamics
8.2.4.4.2 Cancer Incidence (by Type of Cancer)
8.2.4.4.3 Market Size and Forecast
8.2.4.4.3.1 Italy Flow Cytometry in Oncology and Immunology Market (by Application)
8.2.4.4.3.2 Italy Flow Cytometry in Oncology and Immunology Market (by Type of Cancer)
8.2.4.5 Spain
8.2.4.5.1 Market Dynamics
8.2.4.5.2 Cancer Incidence (by Type of Cancer)
8.2.4.5.3 Market Size and Forecast
8.2.4.5.3.1 Spain Flow Cytometry in Oncology and Immunology Market (by Application)
8.2.4.5.3.2 Spain Flow Cytometry in Oncology and Immunology Market (by Type of Cancer)
8.2.4.6 Netherlands
8.2.4.6.1 Market Dynamics
8.2.4.6.2 Cancer Incidence (by Type of Cancer)
8.2.4.6.3 Market Size and Forecast
8.2.4.6.3.1 Netherlands Flow Cytometry in Oncology and Immunology Market (by Application)
8.2.4.6.3.2 Netherlands Flow Cytometry in Oncology and Immunology Market (by Type of Cancer)
8.2.4.7 Rest-of-Europe
8.2.4.7.1 Market Size and Forecast
8.3 Asia-Pacific Flow Cytometry in Oncology and Immunology Market
8.3.1 Key Findings and Opportunity Assessment
8.3.2 Market Dynamics
8.3.2.1 Impact Analysis
8.3.3 Market Sizing and Forecast
8.3.4 Asia-Pacific Flow Cytometry in Oncology and Immunology Market (by Country)
8.3.4.1 China
8.3.4.1.1 Market Dynamics
8.3.4.1.2 Cancer Incidence (by Type of Cancer)
8.3.4.1.3 Market Size and Forecast
8.3.4.1.3.1 China Flow Cytometry in Oncology and Immunology Market (by Application)
8.3.4.1.3.2 China Flow Cytometry in Oncology and Immunology Market (by Type of Cancer)
8.3.4.2 Japan
8.3.4.2.1 Market Dynamics
8.3.4.2.2 Cancer Incidence (by Type of Cancer)
8.3.4.2.3 Market Size and Forecast
8.3.4.2.3.1 Japan Flow Cytometry in Oncology and Immunology Market (by Application)
8.3.4.2.3.2 Japan Flow Cytometry in Oncology and Immunology Market (by Type of Cancer)
8.3.4.3 India
8.3.4.3.1 Market Dynamics
8.3.4.3.2 Cancer Incidence (by Type of Cancer)
8.3.4.3.3 Market Size and Forecast
8.3.4.3.3.1 India Flow Cytometry in Oncology and Immunology Market (by Application)
8.3.4.3.3.2 India Flow Cytometry in Oncology and Immunology Market (by Type of Cancer)
8.3.4.4 Australia
8.3.4.4.1 Market Dynamics
8.3.4.4.2 Cancer Incidence (by Type of Cancer)
8.3.4.4.3 Market Size and Forecast
8.3.4.4.3.1 Australia Flow Cytometry in Oncology and Immunology Market (by Application)
8.3.4.4.3.2 Australia Flow Cytometry in Oncology and Immunology Market (by Type of Cancer)
8.3.4.5 South Korea
8.3.4.5.1 Market Dynamics
8.3.4.5.2 Cancer Incidence (by Type of Cancer)
8.3.4.5.3 Market Size and Forecast
8.3.4.5.3.1 South Korea Flow Cytometry in Oncology and Immunology Market (by Application)
8.3.4.5.3.2 South Korea Flow Cytometry in Oncology and Immunology Market (by Type of Cancer)
8.3.4.6 Singapore
8.3.4.6.1 Market Dynamics
8.3.4.6.2 Cancer Incidence (by Type of Cancer)
8.3.4.6.3 Market Size and Forecast
8.3.4.6.3.1 Singapore Flow Cytometry in Oncology and Immunology Market (by Application)
8.3.4.6.3.2 Singapore Flow Cytometry in Oncology and Immunology Market (by Type of Cancer)
8.3.4.7 Rest-of-Asia-Pacific
8.3.4.7.1 Market Dynamics
8.3.4.7.2 Market Size and Forecast
8.4 Latin America Flow Cytometry in Oncology and Immunology Market
8.4.1 Key Findings and Opportunity Assessment
8.4.2 Market Dynamics
8.4.2.1 Impact Analysis
8.4.3 Market Sizing and Forecast
8.4.4 Latin America Flow Cytometry in Oncology and Immunology Market (by Country)
8.4.4.1 Mexico
8.4.4.1.1 Market Dynamics
8.4.4.1.2 Cancer Incidence (by Type of Cancer)
8.4.4.1.3 Market Size and Forecast
8.4.4.1.3.1 Mexico Flow Cytometry in Oncology and Immunology Market (by Application)
8.4.4.1.3.2 Mexico Flow Cytometry in Oncology and Immunology Market (by Type of Cancer)
8.4.4.2 Brazil
8.4.4.2.1 Market Dynamics
8.4.4.2.2 Cancer Incidence (by Type of Cancer)
8.4.4.2.3 Market Size and Forecast
8.4.4.2.3.1 Brazil Flow Cytometry in Oncology and Immunology Market (by Application)
8.4.4.2.3.2 Brazil Flow Cytometry in Oncology and Immunology Market (by Type of Cancer)
8.4.4.3 Rest-of-Latin America
8.4.4.3.1 Market Dynamics
8.4.4.3.2 Market Size and Forecast
8.5 Rest-of-the-World Flow Cytometry in Oncology and Immunology Market
8.5.1 Key Findings and Opportunity Assessment
8.5.2 Market Dynamics
8.5.2.1 Impact Analysis
8.5.3 Market Sizing and Forecast
9.1 Competitive Landscape
9.1.1 Key Strategies and Developments
9.1.1.1 New Offerings
9.1.1.2 Mergers and Acquisitions
9.1.1.3 Partnerships, Alliances, and Business Expansions
9.1.1.4 Regulatory and Legal Activities
9.1.1.5 Funding Activities
9.2 Market Share Analysis
9.3 Growth-Share Analysis
9.3.1 Company
9.3.2 Technology
9.3.3 Type of Cancer
9.3.4 Application
9.4 Company Profile
9.4.1 Agilent Technologies, Inc
9.4.1.1 Company Overview
9.4.1.2 Role of Agilent Technologies, Inc in the Global Flow Cytometry in Oncology and Immunology Market
9.4.1.3 Financials
9.4.1.4 Key Customers
9.4.1.5 Recent Developments
9.4.1.6 Analyst Perception
9.4.2 Becton, Dickinson and Company
9.4.2.1 Company Overview
9.4.2.2 Role of Becton, Dickinson and Company in the Global Flow Cytometry in Oncology and Immunology Market
9.4.2.3 Financials
9.4.2.4 Key Customers
9.4.2.5 Recent Developments
9.4.2.6 Analyst Perception
9.4.3 Bio-Rad Laboratories, Inc.
9.4.3.1 Company Overview
9.4.3.2 Role of Bio-Rad Laboratories, Inc. in the Global Flow Cytometry in Oncology and Immunology Market
9.4.3.3 Financials
9.4.3.4 Key Customers
9.4.3.5 Recent Developments
9.4.3.6 Analyst Perception
9.4.4 Cell Signaling Technology, Inc.
9.4.4.1 Company Overview
9.4.4.2 Role of Cell Signaling Technology, Inc. in the Global Flow Cytometry in Oncology and Immunology Market
9.4.4.3 Key Customers
9.4.4.4 Analyst Perception
9.4.5 Cytek Biosciences, Inc.
9.4.5.1 Company Overview
9.4.5.2 Role of Cytek Biosciences, Inc. in the Global Flow Cytometry in Oncology and Immunology Market
9.4.5.3 Financials
9.4.5.4 Key Customers
9.4.5.5 Analyst Perception
9.4.6 Danaher Corporation
9.4.6.1 Company Overview
9.4.6.2 Role of Danaher Corporation in the Global Flow Cytometry in Oncology and Immunology Market
9.4.6.3 Financials
9.4.6.4 Key Customers
9.4.6.5 Recent Developments
9.4.6.6 Analyst Perception
9.4.7 DiaSorin S.p.A (Luminex Corporation)
9.4.7.1 Company Overview
9.4.7.2 Role of DiaSorin S.p.A in the Global Flow Cytometry in Oncology and Immunology Market
9.4.7.3 Financials
9.4.7.4 Key Customers
9.4.7.5 Recent Developments
9.4.7.6 Analyst Perception
9.4.8 Enzo Biochem Inc.
9.4.8.1 Company Overview
9.4.8.2 Role of Enzo Biochem Inc. in the Global Flow Cytometry in Oncology and Immunology Market
9.4.8.3 Financials
9.4.8.4 Key Customers
9.4.8.5 Analyst Perception
9.4.9 Laboratory Corporation of America Holdings
9.4.9.1 Company Overview
9.4.9.2 Role of Laboratory Corporation of America Holdings in the Global Flow Cytometry in Oncology and Immunology Market
9.4.9.3 Financials
9.4.9.4 Key Customers
9.4.9.5 Analyst Perception
9.4.10 Merck KGaA
9.4.10.1 Company Overview
9.4.10.2 Role of Merck KGaA in the Global Flow Cytometry in Oncology and Immunology Market
9.4.10.3 Financials
9.4.10.4 Key Customers
9.4.10.5 Analyst Perception
9.4.11 Miltenyi Biotec
9.4.11.1 Company Overview
9.4.11.2 Role of Miltenyi Biotec in the Global Flow Cytometry in Oncology and Immunology Market
9.4.11.3 Key Customers
9.4.11.4 Recent Developments
9.4.11.5 Analyst Perception
9.4.12 NeoGenomics Laboratories, Inc.
9.4.12.1 Company Overview
9.4.12.2 Role of NeoGenomics Laboratories, Inc. in the Global Flow Cytometry in Oncology and Immunology Market
9.4.12.3 Financials
9.4.12.4 Key Customers
9.4.12.5 Recent Developments
9.4.12.6 Analyst Perception
9.4.13 OPKO Health, Inc.
9.4.13.1 Company Overview
9.4.13.2 Role of OPKO Health, Inc. in the Global Flow Cytometry in Oncology and Immunology Market
9.4.13.3 Financials
9.4.13.4 Key Customers
9.4.13.5 Analyst Perception
9.4.14 Sony Group Corporation
9.4.14.1 Company Overview
9.4.14.2 Role of Sony Group Corporation in the Global Flow Cytometry in Oncology and Immunology Market
9.4.14.3 Financials
9.4.14.4 Key Customers
9.4.14.5 Analyst Perception
9.4.15 Thermo Fisher Scientific Inc
9.4.15.1 Company Overview
9.4.15.2 Role of Thermo Fisher Scientific Inc. in the Global Flow Cytometry in Oncology and Immunology Market
9.4.15.3 Financials
9.4.15.4 Key Customers
9.4.15.5 Recent Developments
9.4.15.6 Analyst Perception
Table 1: Key Challenges and Possible Solutions for Stakeholders in the Global Flow Cytometry in Oncology and Immunology Market
Table 2: Global Flow Cytometry in Oncology and Immunology Market, Key Developments Analysis, January 2018-October 2022
Table 3: Key Questions Answered in the Report
Table 4: Presence of Key Healthcare Infrastructure Across the Asia-Pacific Region
Table 5: Global Flow Cytometry in Oncology and Immunology Market, Product Mapping Analysis (by Offering)
Table 6: Global Flow Cytometry in Oncology and Immunology Market, Product Mapping Analysis (by Product)
Table 7: North America Flow Cytometry in Oncology and Immunology Market, Impact Analysis
Table 8: Europe Flow Cytometry in Oncology and Immunology Market, Impact Analysis
Table 9: Asia-Pacific Flow Cytometry in Oncology and Immunology Market, Impact Analysis
Table 10: Latin America Flow Cytometry in Oncology and Immunology Market, Impact Analysis
Table 11: Rest-of-the-World Flow Cytometry in Oncology and Immunology Market, Impact Analysis
Figure 1: Global Flow Cytometry in Oncology and Immunology Market (by End User), $Million, 2021 and 2032
Figure 2: Global Flow Cytometry in Oncology and Immunology Market, Impact Analysis
Figure 3: Global Flow Cytometry in Oncology and Immunology Market (by Region), $Million, 2022 and 2032
Figure 4: Global Flow Cytometry in Oncology and Immunology Market Segmentation
Figure 5: Global Flow Cytometry in Oncology and Immunology Market Research Methodology
Figure 6: Primary Research
Figure 7: Secondary Research
Figure 8: Data Triangulation
Figure 9: Global Flow Cytometry in Oncology and Immunology, Research Process
Figure 10: Assumptions and Limitations
Figure 11: Global Addressable Market Size and Growth Potential ($Million), 2021-2032
Figure 12: Global Addressable Market Size and Growth Potential (by Region), $Million, 2021-2032
Figure 13: Industry Participants Landscape
Figure 14: Increase in Spending on Cancer Care
Figure 15: Cost of Cancer Treatment by Different Groups
Figure 16: Price Sensitivity Analysis
Figure 17: Global Flow Cytometry in Oncology and Immunology Market, Pre-COVID-19, $Million, 2018-2032
Figure 18: Global Flow Cytometry in Oncology and Immunology Market, Impact Analysis
Figure 19: Cancer Prevalence Forecast (by Region) (2020, 2030, and 2040)
Figure 20: Global Flow Cytometry in Oncology and Immunology Market (by Technology)
Figure 21: Flow Cytometry in Oncology and Immunology Market Opportunity (by Technology), $Million, 2021-2032
Figure 22: Global Flow Cytometry in Oncology and Immunology Market (Cell-Based Flow Cytometry), $Million, 2020-2032
Figure 23: Global Flow Cytometry in Oncology and Immunology Market (Bead-Based Flow Cytometry), $Million, 2020-2032
Figure 24: Global Flow Cytometry in Oncology and Immunology Market (by Offering)
Figure 25: Global Flow Cytometry in Oncology and Immunology Market Opportunity (by Offering), $Million, 2021-2032
Figure 26: Global Flow Cytometry in Oncology and Immunology Market (Products), $Million, 2020-2032
Figure 27: Global Flow Cytometry in Oncology and Immunology Market (Instruments), $Million, 2020-2032
Figure 28: Global Flow Cytometry in Oncology and Immunology Market (Reagents and Consumables), $Million, 2020-2032
Figure 29: Global Flow Cytometry in Oncology and Immunology Market (Software), $Million, 2020-2032
Figure 30: Global Flow Cytometry in Oncology and Immunology Market (Services), $Million, 2020-2032
Figure 31: Global Flow Cytometry in Oncology and Immunology Market (by Application)
Figure 32: Global Flow Cytometry in Oncology and Immunology Market Opportunity (by Application), $Million, 2021-2032
Figure 33: Global Flow Cytometry in Oncology and Immunology Market (Translational Research), $Million, 2020-2032
Figure 34: Global Flow Cytometry in Oncology and Immunology Market (Clinical Research), $Million, 2020-2032
Figure 35: Global Flow Cytometry in Oncology and Immunology Market (Screening and Diagnostics), $Million, 2020-2032
Figure 36: Global Flow Cytometry in Oncology and Immunology Market (Monitoring and Treatment), $Million, 2020-2032
Figure 37: Global Flow Cytometry in Oncology and Immunology Market (by Type)
Figure 38: Global Flow Cytometry in Oncology and Immunology Market (by Type), 2021-2032
Figure 39: Global Flow Cytometry in Oncology and Immunology Market (Immunology), $Million, 2020-2032
Figure 40: Global Flow Cytometry in Oncology and Immunology Market (by Oncology), $Million, 2020-2032
Figure 41: Global Flow Cytometry in Oncology and Immunology Market (Oncology (by Type of Cancer))
Figure 42: Global Flow Cytometry in Oncology and Immunology Market (Oncology (by Type of Cancer)), $Million, 2021 and 2032
Figure 43: Global Flow Cytometry in Oncology and Immunology Market (Hematological Malignancies), $Million, 2020-2032
Figure 44: Global Flow Cytometry in Oncology and Immunology Market (by Hematological Malignancies), $Million, 2021 and 2032
Figure 45: Global Flow Cytometry in Oncology and Immunology Market, Hematological Malignancies (Lymphoma), $Million, 2020-2032
Figure 46: Global Flow Cytometry in Oncology and Immunology Market, Hematological Malignancies (Leukemia), $Million, 2020-2032
Figure 47: Global Flow Cytometry in Oncology and Immunology Market, Hematological Malignancies (Myeloma), $Million, 2020-2032
Figure 48: Global Flow Cytometry in Oncology and Immunology Market, Hematological Malignancies (Other Hematological Malignancies), $Million, 2020-2032
Figure 49: Global Flow Cytometry in Oncology and Immunology Market, Hematological Malignancies (by Technology), $Million, 2020-2032
Figure 50: Global Flow Cytometry in Oncology and Immunology Market (Solid Tumor) $Million, 2020-2032
Figure 51: Global Flow Cytometry in Oncology and Immunology Market (by Solid Tumor), $Million, 2021 and 2032
Figure 52: Global Flow Cytometry in Oncology and Immunology Market, Solid Tumor (Breast Cancer), $Million, 2020-2032
Figure 53: Global Flow Cytometry in Oncology and Immunology Market, Solid Tumor (Prostate Cancer), $Million, 2020-2032
Figure 54: Global Flow Cytometry in Oncology and Immunology Market, Solid Tumor (Colorectal Cancer), $Million, 2020-2032
Figure 55: Global Flow Cytometry in Oncology and Immunology Market, Solid Tumor (Lung Cancer), $Million, 2020-2032
Figure 56: Global Flow Cytometry in Oncology and Immunology Market, Solid Tumor (Liver Cancer), $Million, 2020-2032
Figure 57: Global Flow Cytometry in Oncology and Immunology Market, Solid Tumor (Ovarian Cancer), $Million, 2020-2032
Figure 58: Global Flow Cytometry in Oncology and Immunology Market, Solid Tumor (Other Solid Tumors), $Million, 2020-2032
Figure 59: Global Flow Cytometry in Oncology and Immunology Market, Solid Tumor Testing (by Technology), $Million, 2020-2032
Figure 60: Global Flow Cytometry in Oncology and Immunology Market (by End User)
Figure 61: Flow Cytometry in Oncology and Immunology Market Opportunity (by End User), $Million, 2021-2032
Figure 62: Global Flow Cytometry in Oncology and Immunology Market (Hospitals, Diagnostic Laboratories, and Reference Laboratories), $Million, 2020-2032
Figure 63: Global Flow Cytometry in Oncology and Immunology Market (Pharmaceutical and Biotechnology Companies), $Million, 2020-2032
Figure 64: Global Flow Cytometry in Oncology and Immunology Market (Academic Research Institutes), $Million, 2020-20322032
Figure 65: Global Flow Cytometry in Oncology and Immunology Market (Contract Research Organizations), $Million, 2020-2032
Figure 66: Global Flow Cytometry in Oncology and Immunology Market (Others), $Million, 2020-2032
Figure 67: Global Flow Cytometry in Oncology and Immunology Market Share (by Region), 2021-2032
Figure 68: North America Flow Cytometry in Oncology and Immunology Market Incremental Opportunity (by Country), $Million, 2021-2032
Figure 69: North America Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 70: North America Flow Cytometry in Oncology and Immunology Market (by Country), Share (%), 2022 and 2032
Figure 71: Cancer Incidence (by Type of Cancer, Solid Tumor), 2021 vs. 2032
Figure 72: Cancer Incidence (by Type of Cancer, Hematological Malignancies), 2021 vs. 2032
Figure 73: U.S. Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 74: U.S. Flow Cytometry in Oncology and Immunology Market (by Application), $Million, 2020-2032
Figure 75: U.S. Flow Cytometry in Oncology and Immunology Market (by Type of Cancer), $Million, 2020-2032
Figure 76: Cancer Incidence (by Type of Cancer, Solid Tumor), 2021 vs. 2032
Figure 77: Cancer Incidence (by Type of Cancer, Hematological Malignancies), 2021 vs. 2032
Figure 78: Canada Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 79: Canada Flow Cytometry in Oncology and Immunology Market (by Application), $Million, 2020-2032
Figure 80: Canada Flow Cytometry in Oncology and Immunology Market (by Type of Cancer), $Million, 2020-2032
Figure 81: Europe Flow Cytometry in Oncology and Immunology Market Incremental Opportunity (by Country), $Million, 2021-2032
Figure 82: Europe Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 83: Europe Flow Cytometry in Oncology and Immunology Market (by Country), Share (%), 2021 and 2032
Figure 84: Cancer Incidence (by Type of Cancer, Solid Tumor), 2021 vs. 2032
Figure 85: Cancer Incidence (by Type of Cancer, Hematological Malignancies), 2021 vs. 2032
Figure 86: Germany Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 87: Germany Flow Cytometry in Oncology and Immunology Market (by Application), $Million, 2020-2032
Figure 88: Germany Flow Cytometry in Oncology and Immunology Market (by Type of Cancer), $Million, 2020-2032
Figure 89: Cancer Incidence (by Type of Cancer, Solid Tumor), 2021 vs. 2032
Figure 90: Cancer Incidence (by Type of Cancer, Hematological Malignancies), 2021 vs. 2032
Figure 91: France Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 92: France Flow Cytometry in Oncology and Immunology Market (by Application), $Million, 2020-2032
Figure 93: France Flow Cytometry in Oncology and Immunology Market (by Type of Cancer), $Million, 2020-2032
Figure 94: Cancer Incidence (by Type of Cancer, Solid Tumor), 2021 vs. 2032
Figure 95: Cancer Incidence (by Type of Cancer, Hematological Malignancies), 2021 vs. 2032
Figure 96: U.K. Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 97: U.K. Flow Cytometry in Oncology and Immunology Market (by Application), $Million, 2020-2032
Figure 98: U.K. Flow Cytometry in Oncology and Immunology Market (by Type of Cancer), $Million, 2020-2032
Figure 99: Cancer Incidence (by Type of Cancer, Solid Tumor), 2021 vs. 2032
Figure 100: Cancer Incidence (by Type of Cancer, Hematological Malignancies), 2021 vs. 2032
Figure 101: Italy Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 102: Italy Flow Cytometry in Oncology and Immunology Market (by Application), $Million, 2020-2032
Figure 103: Italy Flow Cytometry in Oncology and Immunology Market (by Type of Cancer), $Million, 2020-2032
Figure 104: Cancer Incidence (by Type of Cancer, Solid Tumor), 2021 vs. 2032
Figure 105: Cancer Incidence (by Type of Cancer, Hematological Malignancies), 2021 vs. 2032
Figure 106: Spain Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 107: Spain Flow Cytometry in Oncology and Immunology Market (by Application), $Million, 2020-2032
Figure 108: Spain Flow Cytometry in Oncology and Immunology Market (by Type of Cancer), $Million, 2020-2032
Figure 109: Cancer Incidence (by Type of Cancer, Solid Tumor), 2021 vs. 2032
Figure 110: Cancer Incidence (by Type of Cancer, Hematological Malignancies), 2021 vs. 2032
Figure 111: Netherlands Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 112: Netherlands Flow Cytometry in Oncology and Immunology Market (by Application), $Million, 2020-2032
Figure 113: Netherlands Flow Cytometry in Oncology and Immunology Market (by Type of Cancer), $Million, 2020-2032
Figure 114: Rest-of-Europe Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 115: Asia-Pacific Flow Cytometry in Oncology and Immunology Market Incremental Opportunity (by Country), $Million, 2021-2032
Figure 116: Asia-Pacific Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 117: Asia-Pacific Flow Cytometry in Oncology and Immunology Market (by Country), Share (%), 2022 and 2032
Figure 118: Cancer Incidence (by Type of Cancer, Solid Tumor), 2021 vs. 2032
Figure 119: Cancer Incidence (by Type of Cancer, Hematological Malignancies), 2021 vs. 2032
Figure 120: China Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 121: China Flow Cytometry in Oncology and Immunology Market (by Application), $Million, 2020-2032
Figure 122: China Flow Cytometry in Oncology and Immunology Market (by Type of Cancer), $Million, 2020-2032
Figure 123: Cancer Incidence (by Type of Cancer, Solid Tumor), 2021 vs. 2032
Figure 124: Cancer Incidence (by Type of Cancer, Hematological Malignancies), 2021 vs. 2032
Figure 125: Japan Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 126: Japan Flow Cytometry in Oncology and Immunology Market (by Application), $Million, 2020-2032
Figure 127: Japan Flow Cytometry in Oncology and Immunology Market (by Type of Cancer), $Million, 2020-2032
Figure 128: Cancer Incidence (by Type of Cancer, Solid Tumor), 2021 vs. 2032
Figure 129: Cancer Incidence (by Type of Cancer, Hematological Malignancies), 2021 vs. 2032
Figure 130: India Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 131: India Flow Cytometry in Oncology and Immunology Market (by Application), $Million, 2020-2032
Figure 132: India Flow Cytometry in Oncology and Immunology Market (by Type of Cancer), $Million, 2020-2032
Figure 133: Cancer Incidence (by Type of Cancer, Solid Tumor), 2021 vs. 2032
Figure 134: Cancer Incidence (by Type of Cancer, Hematological Malignancies), 2021 vs. 2032
Figure 135: Australia Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 136: Australia Flow Cytometry in Oncology and Immunology Market (by Application), $Million, 2020-2032
Figure 137: Australia Flow Cytometry in Oncology and Immunology Market (by Type of Cancer), $Million, 2020-2032
Figure 138: Cancer Incidence (by Type of Cancer, Solid Tumor), 2021 vs. 2032
Figure 139: Cancer Incidence (by Type of Cancer, Hematological Malignancies), 2021 vs. 2032
Figure 140: South Korea Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 141: South Korea Flow Cytometry in Oncology and Immunology Market (by Application), $Million, 2020-2032
Figure 142: South Korea Flow Cytometry in Oncology and Immunology Market (by Type of Cancer), $Million, 2020-2032
Figure 143: Cancer Incidence (by Type of Cancer, Solid Tumor), 2021 vs. 2032
Figure 144: Cancer Incidence (by Type of Cancer, Hematological Malignancies), 2021 vs. 2032
Figure 145: Singapore Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 146: Singapore Flow Cytometry in Oncology and Immunology Market (by Application), $Million, 2020-2032
Figure 147: Singapore Flow Cytometry in Oncology and Immunology Market (by Type of Cancer), $Million, 2020-2032
Figure 148: Rest-of-Asia-Pacific Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 149: Latin America Flow Cytometry in Oncology and Immunology Market Incremental Opportunity (by Country), $Million, 2021-2032
Figure 150: Latin America Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 151: Latin America Flow Cytometry in Oncology and Immunology Market (by Country), Share (%), 2022 and 2032
Figure 152: Cancer Incidence (by Type of Cancer, Solid Tumor), 2021 vs. 2032
Figure 153: Cancer Incidence (by Type of Cancer, Hematological Malignancies), 2021 vs. 2032
Figure 154: Mexico Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 155: Mexico Flow Cytometry in Oncology and Immunology Market (by Application), $Million, 2020-2032
Figure 156: Mexico Flow Cytometry in Oncology and Immunology Market (by Type of Cancer), $Million, 2020-2032
Figure 157: Cancer Incidence (by Type of Cancer, Solid Tumor), 2021 vs. 2032
Figure 158: Cancer Incidence (by Type of Cancer, Hematological Malignancies), 2021 vs. 2032
Figure 159: Brazil Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 160: Brazil Flow Cytometry in Oncology and Immunology Market (by Application), $Million, 2020-2032
Figure 161: Brazil Flow Cytometry in Oncology and Immunology Market (by Type of Cancer), $Million, 2020-2032
Figure 162: Rest-of-Latin America Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 163: Rest-of-the-World Flow Cytometry in Oncology and Immunology Market, $Million, 2020-2032
Figure 164: Share of Key Developments and Strategies, January 2018-October 2022
Figure 165: New Offerings (by Company), January 2018-October 2022
Figure 166: Mergers and Acquisitions (by Company), January 2018-October 2022
Figure 167: Partnerships, Alliances, and Business Expansions (by Company), January 2018-October 2022
Figure 168: Regulatory and Legal Activities (by Company), January 2018-October 2022
Figure 169: Funding Activities (by Company), January 2018-October 2022
Figure 170: Global Flow Cytometry in Oncology and Immunology Market, Company Revenue Share Analysis, $Million, 2021
Figure 171: Growth-Share Analysis for Global Flow Cytometry in Oncology and Immunology Market (by Company), 2021
Figure 172: Growth-Share Analysis for Global Flow Cytometry in Oncology and Immunology Market (by Technology), 2021-2032
Figure 173: Growth-Share Analysis for Global Flow Cytometry in Oncology and Immunology Market (by Type of Cancer), 2021-2032
Figure 174: Growth-Share Analysis for Global Flow Cytometry in Oncology and Immunology Market (by Application), 2021-2032
Figure 175: Agilent Technologies, Inc: Product Portfolio
Figure 176: Agilent Technologies, Inc: Overall Financials, $Million, 2019-2021
Figure 177: Agilent Technologies, Inc: Segment Revenues, $Million, 2019-2021
Figure 178: Agilent Technologies, Inc: Net Revenue (by Region), $Million, 2019-2021
Figure 179: Agilent Technologies, Inc: R&D Expenditure, $Million, 2019-2021
Figure 180: Becton, Dickinson and Company: Product Portfolio
Figure 181: Becton, Dickinson and Company: Overall Financials, $Million, 2019-2021
Figure 182: Becton, Dickinson and Company: Segment Revenues, $Million, 2019-2021
Figure 183: Becton, Dickinson and Company: Net Revenue (by Region), $Million, 2019-2021
Figure 184: Becton, Dickinson and Company: R&D Expenditure, $Million, 2019-2021
Figure 185: Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 186: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2019-2021
Figure 187: Bio-Rad Laboratories, Inc.: Segment Revenues, $Million, 2019-2021
Figure 188: Bio-Rad Laboratories, Inc.: Net Revenue (by Region), $Million, 2019-2021
Figure 189: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 190: Cell Signaling Technology, Inc.: Product Portfolio
Figure 191: Cytek Biosciences, Inc.: Product Portfolio
Figure 192: Cytek Biosciences, Inc.: Overall Financials, $Million, 2020-2021
Figure 193: Cytek Biosciences, Inc.: Net Revenue (by Region), $Million, 2020-2021
Figure 194: Cytek Biosciences, Inc.: R&D Expenditure, $Million, 2020-2021
Figure 195: Danaher Corporation: Product Portfolio
Figure 196: Danaher Corporation: Overall Financials, $Million, 2019-2021
Figure 197: Danaher Corporation: Segment Revenues, $Million, 2019-2021
Figure 198: Danaher Corporation: Net Revenue (by Region), $Million, 2019-2021
Figure 199: Danaher Corporation: R&D Expenditure, $Million, 2019-2021
Figure 200: DiaSorin S.p.A: Product Portfolio
Figure 201: DiaSorin S.p.A: Overall Financials, $Million, 2019-2021
Figure 202: DiaSorin S.p.A: Segment Revenues, $Million, 2019-2021
Figure 203: DiaSorin S.p.A: Net Revenue (by Region), $Million, 2019-2021
Figure 204: DiaSorin S.p.A: R&D Expenditure, $Million, 2019-2021
Figure 205: Enzo Biochem Inc.: Product Portfolio
Figure 206: Enzo Biochem Inc.: Overall Financials, $Million, 2020-2022
Figure 207: Enzo Biochem Inc.: Segment Revenues, $Million, 2020-2022
Figure 208: Enzo Biochem Inc.: Net Revenue (by Region), $Million, 2020-2022
Figure 209: Enzo Biochem Inc.: R&D Expenditure, $Million, 2020-2022
Figure 210: Laboratory Corporation of America Holdings: Product Portfolio
Figure 211: Laboratory Corporation of America Holdings: Overall Financials, $Million, 2019-2021
Figure 212: Laboratory Corporation of America Holdings: Segment Revenues, $Million, 2019-2021
Figure 213: Laboratory Corporation of America Holdings: Net Revenue (by Region), $Million, 2020-2021
Figure 214: Merck KGaA: Product Portfolio
Figure 215: Merck KGaA: Overall Financials, $Million, 2019-2021
Figure 216: Merck KGaA: Segment Revenues, $Million, 2020-2021
Figure 217: Merck KGaA: Net Revenue (by Region), $Million, 2019-2021
Figure 218: Merck KGaA: R&D Expenditure, $Million, 2019-2021
Figure 219: Miltenyi Biotec: Product Portfolio
Figure 220: NeoGenomics Laboratories, Inc.: Product Portfolio
Figure 221: NeoGenomics Laboratories, Inc.: Overall Financials, $Million, 2019-2021
Figure 222: NeoGenomics Laboratories, Inc.: Segment Revenues, $Million, 2019-2021
Figure 223: NeoGenomics Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 224: OPKO Health, Inc.: Product Portfolio
Figure 225: OPKO Health, Inc.: Overall Financials, $Million, 2019-2021
Figure 226: OPKO Health, Inc.: Segment Revenues, $Million, 2019-2021
Figure 227: OPKO Health, Inc.: Net Revenue (by Region), $Million, 2019-2021
Figure 228: OPKO Health, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 229: Sony Group Corporation: Product Portfolio
Figure 230: Sony Group Corporation: Overall Financials, $Million, 2019-2021
Figure 231: Sony Group Corporation: Segment Revenues, $Million, 2019-2021
Figure 232: Sony Group Corporation: Net Revenue (by Region), $Million, 2019-2021
Figure 233: Sony Group Corporation: R&D Expenditure, $Million, 2019-2021
Figure 234: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 235: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2019-2021
Figure 236: Thermo Fisher Scientific Inc.: Segment Revenues, $Million, 2019-2021
Figure 237: Thermo Fisher Scientific Inc.: Net Revenue (by Region), $Million, 2019-2021
Figure 238: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2019-2021
Market Report Coverage
|
Flow Cytometry in Oncology and Immunology Market |
|||
|
Base Year |
2021 |
Market Size in 2021 |
$1,653.2 Million |
|
Forecast Period |
2022-2032 |
Value Projection and Estimation by 2032 |
$5,287.4 Million |
|
CAGR During Forecast Period |
11.39% |
Number of Tables |
11 |
|
Number of Pages |
286 |
Number of Figures |
238 |
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
Some of the players in this market are:
• Agilent Technologies, Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Cell Signaling Technology, Inc.
• Cytek Biosciences, Inc.
• Danaher Corporation
• DiaSorin S.p.A (Luminex Corporation)
• Enzi Biochem Inc.
• Laboratory Corporation of America Holdings
• Merck KGaA
• Miltenyi Biotec
• NeoGenomics Laboratories, Inc.
• OPKO Health, Inc.
• Sony Group Corporation
• Thermo Fisher Scientific Inc
How can this report add value to an organization?
Offerings: The offerings segment helps the reader understand the different types of flow cytometry offerings available in the market. Moreover, the study provides the reader with a detailed understanding of products that fall under the two main segments, i.e., products and services.
Growth/Marketing Strategy: The global flow cytometry in oncology and immunology market has witnessed major development by key players operating in the market, such as product launches, business expansions, partnerships, collaborations, mergers and acquisitions, funding activities, and regulatory and legal approvals. The favored strategy for the companies has been new product offerings to strengthen their position in the market. For instance, in June 2022, Becton, Dickinson and Company launched its new cell sorting technology at the International Society for Advancement of Cytometry (ISAC). Using this technology can help in sorting cells at a very fast speed during flow cytometry.
Competitive Strategy: The key players in the global flow cytometry in oncology and immunology market analyzed and profiled in the study involve established and emerging players that offer different products for flow cytometry. Moreover, a detailed competitive benchmarking of the players operating in the global flow cytometry in oncology and immunology market has been done to help the reader understand the ways in which players stack against each other, presenting a clear market landscape. Moreover, comprehensive competitive strategies such as partnerships, agreements, collaborations, mergers, and acquisitions will help the reader understand the untapped revenue pockets in the market.
Industry and Technology Overview
Global Flow Cytometry in Oncology and Immunology Market Industry Overview
The global flow cytometry in oncology and immunology market was valued at $1,653.2 million in 2021 and is anticipated to reach $5,287.4 million by 2032, witnessing a CAGR of 11.39% during the forecast period 2022-2032. The market is driven by factors such as the increasing burden of cancer, expansion of applications in flow cytometry for research activities, innovation in flow cytometry leading to the use of next-generation flow cytometers, and the increasing use of flow cytometry in the identification and diagnosis of immune-deficiency diseases.
Market Lifecycle Stage
The global flow cytometry in the oncology and immunology market is in the developed phase. The increasing research for flow cytometry for the detection of solid tumors and the leveraging of public-private initiatives to advance R&D in the field of immunology and oncology research are some of the major opportunities in the global flow cytometry in oncology and immunology market.
Impact of COVID-19
COVID-19 had a minimal impact on the global flow cytometry in oncology and immunology market. The initial breakout of the pandemic led to an increase in the use of reagents of flow cytometry in research activities and clinical trials. However, the manufacturers witnessed a loss in 2020 due to COVID-19 restrictions and preventive actions such as a reduction in supply chain and sales. Also, there was a significant shift observed toward research activities for treating and diagnosing COVID-19, which resulted in a halt in research activities for oncology using flow cytometry. Besides these minimal impacts, flow cytometry in oncology and immunology is expected to overcome the impact in the forecast period 2022-2032.
Market Segmentation:
Segmentation 1: by Offering
• Products
o Instruments
o Reagents and Consumables
o Software
• Services
The global flow cytometry in oncology and immunology market (by offering) is expected to be dominated by the products segment.
Segmentation 2: by Technology
• Cell-Based Flow Cytometry
• Bead-Based Flow Cytometry
The global flow cytometry in oncology and immunology (by technology) is expected to be dominated by the cell-based flow cytometry segment.
Segmentation 3: by Type
• Immunology
• Oncology
The global flow cytometry in oncology and immunology market (by type) is dominated by the oncology segment.
Segmentation 4: by Application
• Translational Research
• Clinical Research
The global flow cytometry in oncology and immunology market (by application) is dominated by the translational research segment.
Segmentation 5: by End User
• Hospitals, Diagnostic Laboratories, and Reference Laboratories
• Pharmaceutical and Biotechnology Companies
• Academic Research Institutes
• Contract Research Organizations
• Others
The global flow cytometry in oncology and immunology market (by end user) is dominated by the hospitals, diagnostic laboratories, and reference laboratories segment.
Segmentation 6: by Region
• North America - U.S., Canada
• Europe - Germany, France, U.K., Italy, Spain, Netherlands, Rest-of-Europe
• Asia-Pacific - Japan, China, India, Australia, South Korea, Singapore, Rest-of-Asia-Pacific
• Latin America - Brazil, Mexico, Rest-of-Latin America
• Rest-of-the-World
The global flow cytometry in oncology and immunology market (by region) is dominated by the North America segment.
Recent Developments in the Global Flow Cytometry in Oncology and Immunology Market
• In February 2022, Becton, Dickinson and Company acquired Cytognos, S.L. Through this acquisition, the company expanded its flow cytometry portfolio and gained the expertise of ~80 scientists and professionals at Cytognos S.L.
• In September 2022, Becton, Dickinson and Company launched BD Research Cloud, a cloud-based software solution designed to streamline the flow cytometry workflow to enable higher quality experiments with faster time to insight for scientists working across a range of disciplines, including immunology, virology, oncology, and infectious disease monitoring.
• In September 2021, Beckman Coulter, a wholly owned subsidiary of Danaher Corporation, launched its new CytoFLEX flow cytometry platform, which is expected to open new avenues for cancer researchers with respect to single-cell analysis. This new system launched by the company offers powerful analytical performance in a benchtop instrument, which offers high sensitivity.
• In February 2021, Thermo Fisher Scientific Inc. acquired the cell sorting technology assets of Propel Labs, which is expected to broaden Thermo Fisher's flow cytometry and cell analysis portfolio.
• In December 2020, Thermo Fisher Scientific Inc. acquired Phitonex, Inc., a pioneer in the field of spectral dye platforms for high-resolution biological applications, including oncology and immunology. With the acquisition of the company, Thermo Fisher Scientific Inc. is expected to offer greater flow cytometry capabilities to meet evolving customer demands for cell and protein analysis research.
• In January 2020, Luminex Corporation acquired Merck's flow cytometry business portfolio for $75 million, further enabling the company to effectively enhance its existing offerings related to flow-based detection instruments. The company's newly acquired FCM portfolio includes Guava and Amnis product portfolios.
Demand – Drivers and Limitations
Following are the drivers for the global flow cytometry in oncology and immunology market:
• Increasing Burden of Cancer is One of the Major Propelling Factors for the Innovation of Novel Technologies in Flow Cytometry
• Expansion of Applications in Flow Cytometry for Research Activities Propels its Demand in the Market
• Innovation in Flow Cytometry Leading to Use of Next-Generation Flow Cytometers
• Increasing Use of Flow Cytometry in Identification and Diagnosis of Immune-Deficiency Diseases
The market is expected to face some limitations as well due to the following challenges:
• High Cost of the Products of the Flow Cytometry Equipment Restraining the Adoption of the Devices in Emerging Economies
• False Negative and Positive Antibody Responses Can Hinder the Adoption of Flow Cytometry
Analyst’s Thoughts
To emphasize the potential of the global flow cytometry in oncology and immunology market, Swati Sood, Principal Analyst – BIS Research, states, “With the increasing burden of cancer, the demand for flow cytometry has increased worldwide. Flow cytometry provides quick and effective data collection from a heterogenous mixture of fluids. This is primarily due to the extensive adoption of flow cytometry-based products for improving the diagnosis and screening of cancer, particularly hematological malignancies. Additionally, manufacturers are significantly investing in research and development (R&D) to expand their respective product portfolios by developing multiparametric and next-generation flow cytometry solutions for cancer diagnostic testing.”
Flow Cytometry in Oncology and Immunology Market - A Global and Regional Analysis
Focus on Offering, Technology, End User, Type, Application, and Country - Analysis and Forecast, 2022-2032
Some Faq's
Frequently Asked Questions
According to BIS Research, flow cytometry in the field of oncology is utilized for the quantitative detection and measurement of the physical and chemical characteristics of cancerous cells in a given sample. Flow cytometry is majorly used for hematological malignancies to identify malignant cell types by detecting cell surface antigens, which offer critical information regarding the stage of maturation and phenotypical heterogeneity.
The global flow cytometry in oncology and immunology market has witnessed major developments by key players operating in the market, such as business expansions, partnerships, collaborations, regulatory and legal activities, funding activities, product launches, and acquisitions and mergers. According to BIS Research analysis, most of the companies preferred new offerings as a strategy to further increase their growth in the global flow cytometry in oncology and immunology market. Companies such as Becton, Dickinson and Company, DiaSorin S.p.A., Bio-Rad Laboratories, and Agilent Technologies, Inc. have majorly adopted new offerings as their preferred strategy.
A new entrant can focus on developing flow cytometry products for application in solid tumors.
The following can be considered some of the USPs of the report:
• Impact of COVID-19 on the global flow cytometry in oncology and immunology market, including the detailed analysis of pre-COVID-19 and during the COVID-19 scenario, along with the future impact of COVID-19 pandemic on the market
• Extensive product benchmarking of the top players (including established and emerging players) to offer a holistic view of the global flow cytometry in oncology and immunology market product landscape
• Product mapping analysis
• Cancer incidence at the country level
• Market share analysis based on product portfolios, recent developments, and regional spread of the key players
• Reimbursement scenario and regulatory framework
The companies developing, manufacturing, and commercializing products for flow cytometry in oncology and immunology should buy this report.
Similar Product
You may also like